Contact this trialFirst, we need to learn more about you.
CAR T-cell Therapy
RAPA-201 Immunotherapy for Solid Cancers
Recruiting1 awardPhase 1 & 2
Hackensack, New Jersey
This trial is a study of a new cancer treatment called RAPA-201. RAPA-201 is a second-generation immunotherapy product consisting of reprogrammed autologous CD4+ and CD8+ T cells of Th1/Tc1 cytokine phenotype. The study will evaluate the adoptive transfer of RAPA-201 cells in patients with advanced metastatic, recurrent, and unresectable solid tumors that have recurred or relapsed after prior immune therapy.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.